Drug Trial Radar · NCT00490360
Neoadjuvant Chemotherapy for Resectable Cancer of the Pancreatic Head
Last checked: Nov 19, 2026Latest source record: Jun 22, 2007 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,007
Actual
Start
Oct 2001
Primary completion
Not stated
Study completion May 2007
Sponsor
- Lead sponsor
- University of ZurichAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 22, 2007
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Neodajuvant chemotherapy with gemcitabine / cisplatin is applied to patients with resectable cancer of pancreatic head.
Conditions
- Cancer of the Pancreatic Head
Interventions
Gemcitabine / CisplatinDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Resectability rate > 70% after restagingTime frame: 2007
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University Hospital of Zurich, Department of Surgery
Zurich, Switzerland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.